Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erbella
- Development stage
- Unknown
- Lead developer
- Uscare Pharm
- Administration
- Intradermal, Subcutaneous
01
Overview
Erbella is a hybrid dermal filler developed by Uscare Pharm that combines Poly-L-lactic acid (PLLA) and Hyaluronic acid (HA). This combination is designed to provide both immediate and long-lasting aesthetic results. The hyaluronic acid component offers immediate volume restoration and hydration to the skin, while the PLLA microspheres act as a bio-stimulator, triggering the body's natural production of Type I collagen over time. This dual-action mechanism addresses facial volume loss, deep wrinkles, and skin laxity. Erbella is currently marketed as a commercial product for aesthetic rejuvenation.
- Brand names
- Erbella
- Other names
- ERBELLAPLLA+HA dermal filler
Beyond the preview
Go deeper on Erbella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erbella.